Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $14.30.

A number of brokerages recently weighed in on VNDA. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Monday, April 20th. Wall Street Zen cut shares of Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday. HC Wainwright reduced their target price on shares of Vanda Pharmaceuticals from $24.00 to $21.00 and set a “buy” rating for the company in a report on Monday. Zacks Research cut shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 18th. Finally, Truist Financial initiated coverage on shares of Vanda Pharmaceuticals in a report on Thursday, March 5th. They issued a “buy” rating and a $18.00 target price for the company.

Insiders Place Their Bets

In other news, CMO Joakim Wijkstrom sold 30,800 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.27, for a total value of $254,716.00. Following the completion of the sale, the chief marketing officer directly owned 333,469 shares of the company’s stock, valued at approximately $2,757,788.63. This represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Timothy Williams sold 42,434 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $8.27, for a total transaction of $350,929.18. Following the completion of the sale, the senior vice president directly owned 377,450 shares of the company’s stock, valued at $3,121,511.50. The trade was a 10.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 314,342 shares of company stock valued at $2,583,985. 8.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Vanda Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. AIGH Capital Management LLC acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $17,626,000. Russell Investments Group Ltd. increased its stake in shares of Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 5,328 shares during the period. Hsbc Holdings PLC increased its stake in shares of Vanda Pharmaceuticals by 8.8% during the first quarter. Hsbc Holdings PLC now owns 38,855 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 3,144 shares during the period. SG Americas Securities LLC increased its stake in shares of Vanda Pharmaceuticals by 94.7% during the first quarter. SG Americas Securities LLC now owns 21,042 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 10,235 shares during the period. Finally, AXQ Capital LP acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth about $234,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Price Performance

Shares of VNDA opened at $6.27 on Tuesday. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $9.94. The stock has a market cap of $377.02 million, a PE ratio of -1.55 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.16 and a quick ratio of 2.15. The firm has a fifty day moving average price of $7.48 and a 200 day moving average price of $6.81.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.13). Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%. The company had revenue of $51.72 million during the quarter, compared to analysts’ expectations of $54.98 million. As a group, sell-side analysts anticipate that Vanda Pharmaceuticals will post -2.23 EPS for the current year.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.